메뉴 건너뛰기




Volumn 7, Issue 1, 2011, Pages 611-620

Clinical utility of the risperidone formulations in the management of schizophrenia

Author keywords

Antipsychotic; Formulation; Risperidone; Schizophrenia; Side effects

Indexed keywords

AMISULPRIDE; ANTIPARKINSON AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PLACEBO; QUETIAPINE; RISPERIDONE; SERTINDOLE; ZIPRASIDONE; ZOTEPINE; ZUCLOPENTHIXOL;

EID: 80955122614     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/ndt.s14385     Document Type: Review
Times cited : (20)

References (66)
  • 1
    • 0037393956 scopus 로고    scopus 로고
    • Discovering risperidone: The LSD model of psychopathology
    • Colpaert FC. Discovering risperidone: the LSD model of psychopathology. Nat Rev Drug Discov. 2003;2(4):315-320.
    • (2003) Nat Rev Drug Discov , vol.2 , Issue.4 , pp. 315-320
    • Colpaert, F.C.1
  • 2
    • 0038383461 scopus 로고    scopus 로고
    • Pharmacokinetic comparison of fast-disintegrating and conventional tablet formulations of risperidone in healthy volunteers
    • Van Schaick EA, Lechat P, Remmerie BM, Ko G, Lasseter KC, Mannaert E. Pharmacokinetic comparison of fast-disintegrating and conventional tablet formulations of risperidone in healthy volunteers. Clin Ther. 2003;25(6):1687-1699.
    • (2003) Clin Ther , vol.25 , Issue.6 , pp. 1687-1699
    • van Schaick, E.A.1    Lechat, P.2    Remmerie, B.M.3    Ko, G.4    Lasseter, K.C.5    Mannaert, E.6
  • 3
    • 33845419519 scopus 로고    scopus 로고
    • Initial treatment of severe acute psychosis with fast orally disintegrating risperidone tablets
    • Normann C, Schmauss M, Bakri N, Gerwe M, Schreiner A. Initial treatment of severe acute psychosis with fast orally disintegrating risperidone tablets. Pharmacopsychiatry. 2006;39(6):209-212.
    • (2006) Pharmacopsychiatry , vol.39 , Issue.6 , pp. 209-212
    • Normann, C.1    Schmauss, M.2    Bakri, N.3    Gerwe, M.4    Schreiner, A.5
  • 4
    • 77953018117 scopus 로고    scopus 로고
    • Comparison of risperidone orodispersible tablet and intramuscular haloperidol in the treatment of acute psychotic agitation: A randomized open, prospective study
    • Lim HK, Kim JJ, Pae CU, Lee CU, Lee C, Paik IH. Comparison of risperidone orodispersible tablet and intramuscular haloperidol in the treatment of acute psychotic agitation: a randomized open, prospective study. Neuropsychobiology. 2010;62(2):81-86.
    • (2010) Neuropsychobiology , vol.62 , Issue.2 , pp. 81-86
    • Lim, H.K.1    Kim, J.J.2    Pae, C.U.3    Lee, C.U.4    Lee, C.5    Paik, I.H.6
  • 5
    • 0028332094 scopus 로고
    • Survey on the pharmacodynamics of the new antipsychotic risperidone
    • Megens AA, Awouters FH, Schotte A, et al. Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology (Berl). 1994;114(1):9-23.
    • (1994) Psychopharmacology (Berl) , vol.114 , Issue.1 , pp. 9-23
    • Megens, A.A.1    Awouters, F.H.2    Schotte, A.3
  • 6
    • 75349090533 scopus 로고    scopus 로고
    • Risperidone dose for schizophrenia
    • October 7 CD007474
    • Li C, Xia J, Wang J. Risperidone dose for schizophrenia. Cochrane Database Syst Rev. October 7, 2009;(4):CD007474.
    • (2009) Cochrane Database Syst Rev , Issue.4
    • Li, C.1    Xia, J.2    Wang, J.3
  • 8
    • 24344476307 scopus 로고    scopus 로고
    • Control group bias in randomized atypical antipsychotic medication trials for schizophrenia
    • Woods SW, Gueorguieva RV, Baker CB, Makuch RW. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia. Arch Gen Psychiatry. 2005;62(9):961-970.
    • (2005) Arch Gen Psychiatry , vol.62 , Issue.9 , pp. 961-970
    • Woods, S.W.1    Gueorguieva, R.V.2    Baker, C.B.3    Makuch, R.W.4
  • 10
    • 62849099049 scopus 로고    scopus 로고
    • How effective are second-generation antipsychotic drugs? A meta-analysis of placebocontrolled trials
    • Leucht S, Arbter D, Engel RR, Kissling W, Davis JM. How effective are second-generation antipsychotic drugs? A meta-analysis of placebocontrolled trials. Mol Psychiatry. 2009;14(4):429-447.
    • (2009) Mol Psychiatry , vol.14 , Issue.4 , pp. 429-447
    • Leucht, S.1    Arbter, D.2    Engel, R.R.3    Kissling, W.4    Davis, J.M.5
  • 13
    • 79960533801 scopus 로고    scopus 로고
    • Effectiveness of haloperidol, risperidone and olanzapine in the treatment of first-episode non-affective psychosis: Results of a randomized, flexible-dose, openlabel 1-year follow-up comparison
    • doi: 10.1177/0269881110388332
    • Crespo-Facorro B, Pérez-Iglesias RO, Mata I, et al. Effectiveness of haloperidol, risperidone and olanzapine in the treatment of first-episode non-affective psychosis: results of a randomized, flexible-dose, openlabel 1-year follow-up comparison. J Psychopharmacol. 2011. doi: 10.1177/0269881110388332.
    • (2011) J Psychopharmacol
    • Crespo-Facorro, B.1    Pérez-Iglesias, R.O.2    Mata, I.3
  • 15
    • 58049157203 scopus 로고    scopus 로고
    • Secondgeneration versus first-generation antipsychotic drugs for schizophrenia: A meta-analysis
    • Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Secondgeneration versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373(9657):31-41.
    • (2009) Lancet , vol.373 , Issue.9657 , pp. 31-41
    • Leucht, S.1    Corves, C.2    Arbter, D.3    Engel, R.R.4    Li, C.5    Davis, J.M.6
  • 16
    • 60349086480 scopus 로고    scopus 로고
    • A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia
    • Leucht S, Komossa K, Rummel-Kluge C, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry. 2009;166(2):152-163.
    • (2009) Am J Psychiatry , vol.166 , Issue.2 , pp. 152-163
    • Leucht, S.1    Komossa, K.2    Rummel-Kluge, C.3
  • 17
    • 67650505849 scopus 로고    scopus 로고
    • The CATIE and CUtLASS studies in schizophrenia: Results and implications for clinicians
    • Naber D, Lambert M. The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians. CNS Drugs. 2009; 23(8):649-659.
    • (2009) CNS Drugs , vol.23 , Issue.8 , pp. 649-659
    • Naber, D.1    Lambert, M.2
  • 18
    • 35048837486 scopus 로고    scopus 로고
    • The CATIE schizophrenia trial: Results, impact, controversy
    • Manschreck TC, Boshes RA. The CATIE schizophrenia trial: results, impact, controversy. Harv Rev Psychiatry. 2007;15(5):245-258.
    • (2007) Harv Rev Psychiatry , vol.15 , Issue.5 , pp. 245-258
    • Manschreck, T.C.1    Boshes, R.A.2
  • 19
    • 71249090407 scopus 로고    scopus 로고
    • Psychopharmacology and adverse effects of antipsychotic long-acting injections: A review
    • Taylor D. Psychopharmacology and adverse effects of antipsychotic long-acting injections: a review. Br J Psychiatry Suppl. 2009;52: S13-S19.
    • (2009) Br J Psychiatry Suppl , vol.52
    • Taylor, D.1
  • 20
    • 0038149626 scopus 로고    scopus 로고
    • Long-acting injectable risperidone: Efficacy and safety of the first long-acting atypical antipsychotic
    • Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry. 2003;160(6): 1125-1132.
    • (2003) Am J Psychiatry , vol.160 , Issue.6 , pp. 1125-1132
    • Kane, J.M.1    Eerdekens, M.2    Lindenmayer, J.P.3    Keith, S.J.4    Lesem, M.5    Karcher, K.6
  • 22
    • 78649903563 scopus 로고    scopus 로고
    • The impact on schizophrenia-related hospital utilization and costs of switching to long-acting risperidone injections in Sweden
    • Willis M, Svensson M, Löthgren M, Eriksson B, Berntsson A, Persson U. The impact on schizophrenia-related hospital utilization and costs of switching to long-acting risperidone injections in Sweden. Eur J Health Econ. 2010;11(6):585-594.
    • (2010) Eur J Health Econ , vol.11 , Issue.6 , pp. 585-594
    • Willis, M.1    Svensson, M.2    Löthgren, M.3    Eriksson, B.4    Berntsson, A.5    Persson, U.6
  • 23
    • 79951609794 scopus 로고    scopus 로고
    • Clinical outcomes of long-acting injectable risperidone in patients with schizophrenia: Six-month follow-up from the Electronic Schizophrenia Treatment Adherence Registry in Latin America
    • Apiquian R, Córdoba R, Louzã M. Clinical outcomes of long-acting injectable risperidone in patients with schizophrenia: six-month follow-up from the Electronic Schizophrenia Treatment Adherence Registry in Latin America. Neuropsychiatr Dis Treat. 2010;7:19-26.
    • (2010) Neuropsychiatr Dis Treat , vol.7 , pp. 19-26
    • Apiquian, R.1    Córdoba, R.2    Louzã, M.3
  • 24
    • 76949089882 scopus 로고    scopus 로고
    • Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries
    • Peuskens J, Olivares JM, Pecenak J, et al. Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries. Curr Med Res Opin. 2010;26(3):501-509.
    • (2010) Curr Med Res Opin , vol.26 , Issue.3 , pp. 501-509
    • Peuskens, J.1    Olivares, J.M.2    Pecenak, J.3
  • 25
    • 77950944922 scopus 로고    scopus 로고
    • Safety and efficacy of long-acting injectable risperidone in daily practice: An open-label, noninterventional, prospective study in schizophrenia and related disorders
    • Parellada E, Kouniakis F, Siurkute A, Schreiner A, Don L. Safety and efficacy of long-acting injectable risperidone in daily practice: an open-label, noninterventional, prospective study in schizophrenia and related disorders. Int Clin Psychopharmacol. 2010;25(3):149-154.
    • (2010) Int Clin Psychopharmacol , vol.25 , Issue.3 , pp. 149-154
    • Parellada, E.1    Kouniakis, F.2    Siurkute, A.3    Schreiner, A.4    Don, L.5
  • 26
    • 33746676344 scopus 로고    scopus 로고
    • Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity
    • Rubio G, Martinez I, Ponce G, Jimenez-Arriero MA, Lopez-Munoz F, Alamo C. Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity. Can J Psychiatry. 2006;51(8):531-539.
    • (2006) Can J Psychiatry , vol.51 , Issue.8 , pp. 531-539
    • Rubio, G.1    Martinez, I.2    Ponce, G.3    Jimenez-Arriero, M.A.4    Lopez-Munoz, F.5    Alamo, C.6
  • 27
    • 41049103316 scopus 로고    scopus 로고
    • Long-acting injectable risperidone in the treatment of subjects with recent-onset psychosis
    • Emsley R, Medori R, Koen L, Oosthuizen PP, Niehaus D, Rabinowitz J. Long-acting injectable risperidone in the treatment of subjects with recent-onset psychosis. J Clin Psychopharm. 2008;28(2):210-213.
    • (2008) J Clin Psychopharm , vol.28 , Issue.2 , pp. 210-213
    • Emsley, R.1    Medori, R.2    Koen, L.3    Oosthuizen, P.P.4    Niehaus, D.5    Rabinowitz, J.6
  • 28
    • 71249128749 scopus 로고    scopus 로고
    • Second-generation antipsychotic long-acting injections: Systematic review
    • Fleischhacker WW. Second-generation antipsychotic long-acting injections: systematic review. Br J Psychiatry Suppl. 2009;52:S29-S36.
    • (2009) Br J Psychiatry Suppl , vol.52
    • Fleischhacker, W.W.1
  • 29
    • 0022386130 scopus 로고
    • Childhood schizophrenia: A review and comparison of adult onset schizophrenia
    • Beitchman JH, Childhood schizophrenia: a review and comparison of adult onset schizophrenia. Psychiatric Clin North Am. 1985;8(4): 793-814.
    • (1985) Psychiatric Clin North Am , vol.8 , Issue.4 , pp. 793-814
    • Beitchman, J.H.1
  • 30
    • 63449085188 scopus 로고    scopus 로고
    • Risperidone: A review of efficacy studies in adolescents with schizophrenia
    • Madaan V. Risperidone: a review of efficacy studies in adolescents with schizophrenia. Drugs Today (Barc). 2009;45(1):55-62.
    • (2009) Drugs Today (Barc) , vol.45 , Issue.1 , pp. 55-62
    • Madaan, V.1
  • 31
    • 70350546566 scopus 로고    scopus 로고
    • A 6-week, randomized, double blind, placebo controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia
    • Haas M, Unis AS, Armenteros J, Copenhaver MD, Quiroz JA, Kushner SF. A 6-week, randomized, double blind, placebo controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia. J Child Adolesc Psychopharmacol. 2009;19(6):611-621.
    • (2009) J Child Adolesc Psychopharmacol , vol.19 , Issue.6 , pp. 611-621
    • Haas, M.1    Unis, A.S.2    Armenteros, J.3    Copenhaver, M.D.4    Quiroz, J.A.5    Kushner, S.F.6
  • 32
    • 50949132203 scopus 로고    scopus 로고
    • Comparison of two risperidone dose ranges inadolescents with schizophrenia
    • [abstract], October 23-28, Boston, MA
    • Pandina G, Kushner S, Singer J, et al. Comparison of two risperidone dose ranges inadolescents with schizophrenia [abstract]. 54th Annu Meet Am Acad Child Adolesc Psychiatry. October 23-28, 2007; Boston, MA.
    • (2007) 54th Annu Meet Am Acad Child Adolesc Psychiatry
    • Pandina, G.1    Kushner, S.2    Singer, J.3
  • 33
    • 29944441899 scopus 로고    scopus 로고
    • Risperidone-induced prolactin elevation in a prospective study of children, adolescents, and adults with mental retardation and pervasive developmental disorders
    • Hellings JA, Zarcone JR, Valdovinos MG, Reese RM, Gaughan E, Schroeder SR. Risperidone-induced prolactin elevation in a prospective study of children, adolescents, and adults with mental retardation and pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2005;15(6):885-892.
    • (2005) J Child Adolesc Psychopharmacol , vol.15 , Issue.6 , pp. 885-892
    • Hellings, J.A.1    Zarcone, J.R.2    Valdovinos, M.G.3    Reese, R.M.4    Gaughan, E.5    Schroeder, S.R.6
  • 34
    • 0032431939 scopus 로고    scopus 로고
    • Use of atypical neuroleptics in child and adolescent psychiatry
    • Toren P, Loar N, Weizman A. Use of atypical neuroleptics in child and adolescent psychiatry. J Clin Psychiatry. 1998;59(12):644-656.
    • (1998) J Clin Psychiatry , vol.59 , Issue.12 , pp. 644-656
    • Toren, P.1    Loar, N.2    Weizman, A.3
  • 36
    • 0029125796 scopus 로고
    • Case study: Risperidone in children and adolescents with schizophrenia
    • Quintana H, Keshavan M. Case study: risperidone in children and adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry. 1995;34(10):1292-1296.
    • (1995) J Am Acad Child Adolesc Psychiatry , vol.34 , Issue.10 , pp. 1292-1296
    • Quintana, H.1    Keshavan, M.2
  • 37
    • 28444479788 scopus 로고    scopus 로고
    • Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents
    • Correll CU, Penzer JB, Parikh UH, et al. Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents. Child Adolesc Psychiatric Clin N Am. 2006;15(1):177-206.
    • (2006) Child Adolesc Psychiatric Clin N Am , vol.15 , Issue.1 , pp. 177-206
    • Correll, C.U.1    Penzer, J.B.2    Parikh, U.H.3
  • 39
    • 70049104227 scopus 로고    scopus 로고
    • Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia
    • CD006324
    • Cipriani A, Boso M, Barbui C. Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia. Cochrane Database Syst Rev. 2009;(3):CD006324.
    • (2009) Cochrane Database Syst Rev , Issue.3
    • Cipriani, A.1    Boso, M.2    Barbui, C.3
  • 40
    • 65349163482 scopus 로고    scopus 로고
    • Does the addition of a second antipsychotic drug improve clozapine treatment?
    • Barbui C, Signoretti A, Mulè S, Boso M, Cipriani A. Does the addition of a second antipsychotic drug improve clozapine treatment? Schizophr Bull. 2009;35(2):458-468.
    • (2009) Schizophr Bull , vol.35 , Issue.2 , pp. 458-468
    • Barbui, C.1    Signoretti, A.2    Mulè, S.3    Boso, M.4    Cipriani, A.5
  • 41
    • 53049101046 scopus 로고    scopus 로고
    • Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder
    • Houthoofd SA, Morrens M, Sabbe BG. Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder. Clin Ther. 2008;30(9):1565-1589.
    • (2008) Clin Ther , vol.30 , Issue.9 , pp. 1565-1589
    • Houthoofd, S.A.1    Morrens, M.2    Sabbe, B.G.3
  • 42
    • 78650943515 scopus 로고    scopus 로고
    • Mirtazapine augmentation enhances cognitive and reduces negative symptoms in schizophrenia patients treated with risperidone: A randomized controlled trial
    • Cho SJ, Yook K, Kim B, et al. Mirtazapine augmentation enhances cognitive and reduces negative symptoms in schizophrenia patients treated with risperidone: a randomized controlled trial. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(1):208-211.
    • (2011) Prog Neuropsychopharmacol Biol Psychiatry , vol.35 , Issue.1 , pp. 208-211
    • Cho, S.J.1    Yook, K.2    Kim, B.3
  • 43
    • 74449083580 scopus 로고    scopus 로고
    • The effect of mirtazapine add on therapy to risperidone in the treatment of schizophrenia: A double-blind randomized placebo-controlled trial
    • Abbasi SH, Behpournia H, Ghoreshi A, et al. The effect of mirtazapine add on therapy to risperidone in the treatment of schizophrenia: a double-blind randomized placebo-controlled trial. Schizophr Res. 2010;116(2-3):101-106.
    • (2010) Schizophr Res , vol.116 , Issue.2-3 , pp. 101-106
    • Abbasi, S.H.1    Behpournia, H.2    Ghoreshi, A.3
  • 44
    • 0036490550 scopus 로고    scopus 로고
    • Fluvoxamine augmentation in risperidone-resistant schizophrenia: An open trial
    • Takahashi H, Sugita T, Higuchi H, Shimizu T. Fluvoxamine augmentation in risperidone-resistant schizophrenia: an open trial. Hum Psychopharmacol. 2002;17(2):95-98.
    • (2002) Hum Psychopharmacol , vol.17 , Issue.2 , pp. 95-98
    • Takahashi, H.1    Sugita, T.2    Higuchi, H.3    Shimizu, T.4
  • 45
    • 67649723855 scopus 로고    scopus 로고
    • Mirtazapine add-on therapy in the treatment of schizophrenia with atypical antipsychotics: A double-blind, randomised, placebo-controlled clinical trial
    • Berk M, Gama CS, Sundram S, et al. Mirtazapine add-on therapy in the treatment of schizophrenia with atypical antipsychotics: a double-blind, randomised, placebo-controlled clinical trial. Hum Psychopharmacol. 2009;24(3)233-238.
    • (2009) Hum Psychopharmacol , vol.24 , Issue.3 , pp. 233-238
    • Berk, M.1    Gama, C.S.2    Sundram, S.3
  • 46
    • 0034014381 scopus 로고    scopus 로고
    • Novel antipsychotics: Issues and controversies. Typicality of atypical antipsychotics
    • Stip E. Novel antipsychotics: issues and controversies. Typicality of atypical antipsychotics. J Psychiatry Neurosci. 2000;25(2):137-153.
    • (2000) J Psychiatry Neurosci , vol.25 , Issue.2 , pp. 137-153
    • Stip, E.1
  • 47
    • 80955150801 scopus 로고    scopus 로고
    • Medscape
    • Available at
    • Medscape. Drugs, Diseases and Procedures: Risperidone. Available at: http://reference.medscape.com/drug/risperdal-consta-risperidone-342986#0.
    • Drugs, Diseases and Procedures: Risperidone
  • 48
    • 1542373740 scopus 로고    scopus 로고
    • Lower risk for tardive dyskinesia associated with second-generation antipsychotics: A systematic review of 1-year studies
    • Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry. 2004;161(3):414-425.
    • (2004) Am J Psychiatry , vol.161 , Issue.3 , pp. 414-425
    • Correll, C.U.1    Leucht, S.2    Kane, J.M.3
  • 49
    • 0033065629 scopus 로고    scopus 로고
    • Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients
    • Jeste DV, Lacro JP, Bailey A, Rockwell E, Harris MJ, Caligiuri MP. Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients. J Am Geriatr Soc. 1999;47(6): 716-719.
    • (1999) J Am Geriatr Soc , vol.47 , Issue.6 , pp. 716-719
    • Jeste, D.V.1    Lacro, J.P.2    Bailey, A.3    Rockwell, E.4    Harris, M.J.5    Caligiuri, M.P.6
  • 50
    • 77957267779 scopus 로고    scopus 로고
    • Incidence of extrapyramidal symptoms and tardive dyskinesia in schizophrenia: Thirty-six-month results from the European schizophrenia outpatient health outcomes study
    • Novick D, Haro JM, Bertsch J, Haddad PM. Incidence of extrapyramidal symptoms and tardive dyskinesia in schizophrenia: thirty-six-month results from the European schizophrenia outpatient health outcomes study. J Clin Psychopharmacol. 2010;30(5):531-540.
    • (2010) J Clin Psychopharmacol , vol.30 , Issue.5 , pp. 531-540
    • Novick, D.1    Haro, J.M.2    Bertsch, J.3    Haddad, P.M.4
  • 51
    • 34548394992 scopus 로고    scopus 로고
    • Metabolic effects of atypical antipsychotics
    • Wooten J. Metabolic effects of atypical antipsychotics. South Med J. 2007;100(8):771-772.
    • (2007) South Med J , vol.100 , Issue.8 , pp. 771-772
    • Wooten, J.1
  • 52
    • 1842844950 scopus 로고    scopus 로고
    • American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity
    • Consensus development conference on antipsychotic drugs and obesity and diabetes
    • Consensus development conference on antipsychotic drugs and obesity and diabetes. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. J Clin Psychiatry. 2004; 65(2):267-272.
    • (2004) J Clin Psychiatry , vol.65 , Issue.2 , pp. 267-272
  • 53
    • 65749092920 scopus 로고    scopus 로고
    • Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review
    • Simon V, van Winkel R, De Hert M. Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review. J Clin Psychiatry. 2009;70(7):1041-1050.
    • (2009) J Clin Psychiatry , vol.70 , Issue.7 , pp. 1041-1050
    • Simon, V.1    van Winkel, R.2    de Hert, M.3
  • 54
    • 44949234588 scopus 로고    scopus 로고
    • First- vs second-generation antipsychotics and risk for diabetes in schizophrenia: Systematic review and meta-analysis
    • Smith M, Hopkins D, Peveler RC, Holt RI, Woodward M, Ismail K. First- vs second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis. Br J Psychiatry. 2008;192(6):406-411.
    • (2008) Br J Psychiatry , vol.192 , Issue.6 , pp. 406-411
    • Smith, M.1    Hopkins, D.2    Peveler, R.C.3    Holt, R.I.4    Woodward, M.5    Ismail, K.6
  • 55
    • 77953924907 scopus 로고    scopus 로고
    • Hyperprolactinemia associated with psychotropics - a review
    • Madhusoodanan S, Parida S, Jimenez C. Hyperprolactinemia associated with psychotropics - a review. Hum Psychopharmacol. 2010;25(4): 281-297.
    • (2010) Hum Psychopharmacol , vol.25 , Issue.4 , pp. 281-297
    • Madhusoodanan, S.1    Parida, S.2    Jimenez, C.3
  • 56
    • 68749091044 scopus 로고    scopus 로고
    • Tolerability of atypical antipsychotics in the treatment of adults with schizophrenia or bipolar disorder: A mixed treatment comparison of randomized controlled trials
    • Edwards SJ, Smith CJ. Tolerability of atypical antipsychotics in the treatment of adults with schizophrenia or bipolar disorder: a mixed treatment comparison of randomized controlled trials. Clin Ther. 2009;31 Pt 1:1345-1359.
    • (2009) Clin Ther , vol.31 , Issue.PART. 1 , pp. 1345-1359
    • Edwards, S.J.1    Smith, C.J.2
  • 57
    • 66749158086 scopus 로고    scopus 로고
    • Neuroleptic malignant syndrome associated with atypical antipsychotic drugs
    • Trollor JN, Chen X, Sachdev PS. Neuroleptic malignant syndrome associated with atypical antipsychotic drugs. CNS Drugs. 2009;23(6): 477-492.
    • (2009) CNS Drugs , vol.23 , Issue.6 , pp. 477-492
    • Trollor, J.N.1    Chen, X.2    Sachdev, P.S.3
  • 59
    • 0036215480 scopus 로고    scopus 로고
    • Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia
    • Newcomer JW, Haupt DW, Fucetola R, et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry. 2002;59(4):337-345.
    • (2002) Arch Gen Psychiatry , vol.59 , Issue.4 , pp. 337-345
    • Newcomer, J.W.1    Haupt, D.W.2    Fucetola, R.3
  • 61
    • 77957923642 scopus 로고    scopus 로고
    • Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis
    • Rummel-Kluge C, Komossa K, Schwarz S, et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res. 2010;123(2-3):225-233.
    • (2010) Schizophr Res , vol.123 , Issue.2-3 , pp. 225-233
    • Rummel-Kluge, C.1    Komossa, K.2    Schwarz, S.3
  • 62
    • 47249104675 scopus 로고    scopus 로고
    • The evolution of drug development in schizophrenia: Past issues and future opportunities
    • Carpenter WT, Koenig JI. The evolution of drug development in schizophrenia: past issues and future opportunities. Neuropsychopharmacology. 2008;33(9):2061-2079.
    • (2008) Neuropsychopharmacology , vol.33 , Issue.9 , pp. 2061-2079
    • Carpenter, W.T.1    Koenig, J.I.2
  • 63
    • 0034598111 scopus 로고    scopus 로고
    • Atypical antipsychotics in the treatment of schizophrenia: Systematic overview and meta-regression analysis
    • Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ. 2000;321(7273):1371-1376.
    • (2000) BMJ , vol.321 , Issue.7273 , pp. 1371-1376
    • Geddes, J.1    Freemantle, N.2    Harrison, P.3    Bebbington, P.4
  • 64
    • 0038653525 scopus 로고    scopus 로고
    • A meta-analysis of the efficacy of second-generation antipsychotics
    • Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry. 2003;60(6): 553-564.
    • (2003) Arch Gen Psychiatry , vol.60 , Issue.6 , pp. 553-564
    • Davis, J.M.1    Chen, N.2    Glick, I.D.3
  • 65
    • 33747185865 scopus 로고    scopus 로고
    • Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: Observational follow-up study
    • Tiihonen J, Wahlbeck K, Lönnqvist J, et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ. 2006;333(7561):224.
    • (2006) BMJ , vol.333 , Issue.7561 , pp. 224
    • Tiihonen, J.1    Wahlbeck, K.2    Lönnqvist, J.3
  • 66
    • 33751102906 scopus 로고    scopus 로고
    • Remission and relapse in the outpatient care of schizophrenia: Three-year results from the Schizophrenia Outpatient Health Outcomes study
    • SOHO Study Group
    • Haro JM, Novick D, Suarez D, Alonso J, Lépine JP, Ratcliffe M; SOHO Study Group. Remission and relapse in the outpatient care of schizophrenia: three-year results from the Schizophrenia Outpatient Health Outcomes study. J Clin Psychopharmacol. 2006;26(6): 571-578.
    • (2006) J Clin Psychopharmacol , vol.26 , Issue.6 , pp. 571-578
    • Haro, J.M.1    Novick, D.2    Suarez, D.3    Alonso, J.4    Lépine, J.P.5    Ratcliffe, M.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.